Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

BACKGROUND: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic St...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Stroke J
Main Authors: Hart, Robert G, Sharma, Mukul, Mundl, Hardi, Shoamanesh, Ashkan, Kasner, Scott E, Berkowitz, Scott D, Pare, Guillaume, Kirsch, Bodo, Pogue, Janice, Pater, Calin, Peters, Gary, Davalos, Antoni, Lang, Wilfried, Wang, Yongjun, Wang, Yilong, Cunha, Luis, Eckstein, Jens, Tatlisumak, Turgut, Shamalov, Nikolay, Mikulik, Robert, Lavados, Pablo, Hankey, Graeme J, Czlonkowska, Anna, Toni, Danilo, Ameriso, Sebastian F, Gagliardi, Rubens J, Amarenco, Pierre, Bereczki, Daniel, Uchiyama, Shinichiro, Lindgren, Arne, Endres, Matthias, Brouns, Raf, Yoon, Byung-Woo, Ntaios, George, Veltkamp, Roland, Muir, Keith W, Ozturk, Serefnur, Arauz, Antonio, Bornstein, Natan, Bryer, Alan, O’Donnell, Martin J, Weitz, Jeffrey, Peacock, Frank, Themeles, Ellison, Connolly, Stuart J
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2016
Assuntos:
Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6301240/
https://ncbi.nlm.nih.gov/pubmed/31008276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2396987316663049
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares